Douglas Tremblay, MD

home / authors / douglas-tremblay-md

Douglas Tremblay, MD, is an assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Articles

Evaluating Cytoreductive Approaches in MPNs

August 6th 2024

Douglas Tremblay, MD, discusses the different cytoreduction approaches available to patients with myeloproliferative neoplasms and their safety profiles.

Tremblay's Approach to Cytoreduction Across MPNs

Douglas Tremblay, MD

January 31st 2024

Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Tremblay on the Use of Cytoreductive Therapy in PV and ET

Douglas Tremblay, MD

January 8th 2024

Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Integrating Mutational Analysis Into the Clinical Management of Patients With Myelofibrosis

Douglas Tremblay, MD;

June 12th 2018

Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, progressive cytopenias, and transformation to acute myeloid leukemia. This review will describe mutations detected in myelofibrosis and discuss how to incorporate mutation information into risk stratification and therapeutic decision making for patients with myelofibrosis.